Helping Patients Who Don’t Respond to Common Bladder Cancer Treatment

(StatePoint) The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus Calmette–Guérin (BCG), the most common intravesical immunotherapy for early-stage bladder cancer.

However, as options expand, clinicians face added complexity in individualizing treatment paths, and in knowing what’s working. Fortunately, during evaluation and follow-up, they can lean on various enhanced diagnostic technologies, including approaches such as Blue Light Cystoscopy (BLC), to support timely adjustments in treatment.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Post a comment
Stop watching this discussion.